Key result
Transcatheter aortic valve implantation demonstrated noninferiority to surgical aortic valve replacement for mortality at 30 days and 1 year in high-risk elderly patients with aortic stenosis.
Why the study?
Does transcatheter aortic valve implantation (TAVI) improve outcomes compared to surgical aortic valve replacement in elderly patients with symptomatic aortic stenosis at high surgical risk?
Does transcatheter aortic valve implantation (TAVI) improve outcomes compared to surgical aortic valve replacement in elderly patients with symptomatic aortic stenosis at high surgical risk?
TAVI is a safe, cost-effective, and noninferior alternative to surgical aortic valve replacement for mortality in high-risk elderly patients with symptomatic aortic stenosis, despite a higher stroke risk.
Answers are grounded in this paper and cite their sources.
Supports TAVI consideration in high-risk elderly aortic stenosis; leaves open long-term durability and stroke risk questions.
Degenerative aortic stenosis is common over the age of 75 years. Transcatheter aortic valve implantation (TAVI) is a viable therapeutic substitute for symptomatic patients who are at high risk for surgical aortic valve replacement. Multicenter trials demonstrate noninferiority of TAVI compared with aortic valve replacement in a very high-risk population with respect to mortality at 30 days and 1 year, although the stroke rate was higher in the TAVI cohort. Age is not a predictor of mortality despite high prevalence of multiple comorbidities in elderly patients undergoing TAVI. Moreover, TAVI produces significant increases in functional capacity and quality of life. At a time of increasing population age, TAVI is a safe, cost-effective alternative to surgical aortic valve replacement in an elderly population with symptomatic aortic stenosis.
No takes yet. Share an insight, caveat, or question.
Duncan et al. (2012) conducted a review in Symptomatic aortic stenosis. Transcatheter aortic valve implantation (TAVI) vs. Surgical aortic valve replacement was evaluated on Mortality at 30 days and 1 year. Transcatheter aortic valve implantation demonstrated noninferiority to surgical aortic valve replacement for mortality at 30 days and 1 year in high-risk elderly patients with aortic stenosis.
Synapse has enriched 10 related papers. Consider them for comparative context: